Loading…

Berberine improves DSS-induced colitis in mice by modulating the fecal-bacteria-related bile acid metabolism

Ulcerative colitis (UC) has been confirmed as a disease with a high incidence and low cure rate worldwide. In severe cases, UC can develop into colon cancer. Modern research has confirmed that berberine (BBR) can treat UC by inhibiting the expressions of inflammatory factors. However, the contributi...

Full description

Saved in:
Bibliographic Details
Published in:Biomedicine & pharmacotherapy 2023-11, Vol.167, p.115430-115430, Article 115430
Main Authors: Sun, Xiongjie, Zhang, Yu, Cheng, Gang, Zhu, Tianxiang, Zhang, Zhigang, Xiong, Lei, Hu, Haiming, Liu, Hongtao
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c385t-198e623ecccc30234ca55959c15a59d609c7d9bc8a3af6180827e0e3ed4d9f703
cites cdi_FETCH-LOGICAL-c385t-198e623ecccc30234ca55959c15a59d609c7d9bc8a3af6180827e0e3ed4d9f703
container_end_page 115430
container_issue
container_start_page 115430
container_title Biomedicine & pharmacotherapy
container_volume 167
creator Sun, Xiongjie
Zhang, Yu
Cheng, Gang
Zhu, Tianxiang
Zhang, Zhigang
Xiong, Lei
Hu, Haiming
Liu, Hongtao
description Ulcerative colitis (UC) has been confirmed as a disease with a high incidence and low cure rate worldwide. In severe cases, UC can develop into colon cancer. Modern research has confirmed that berberine (BBR) can treat UC by inhibiting the expressions of inflammatory factors. However, the contribution of gut microbiota and flora metabolites in treating UC with BBR remains unclear. In this study, the ameliorative effects of BBR on gut microbiota dysbiosis and flora metabolites were investigated in a dextran sodium sulfate (DSS)-induced UC rodent model. We found that BBR significantly improved the pathological phenotype, attenuated intestinal barrier disruption, and mitigated colonic inflammation in DSS mice. By 16 S rDNA sequencing, BBR alleviated gut microbiota dysbiosis in UC mice. Moreover, the gut microbiota depletion experiment confirmed that the therapeutic effect of BBR was inextricably correlated with the gut microbiota. Besides, the flora metabolites (e.g., short-chain fatty acids, bile acids, and 5-hydroxytryptamine) were studied using HPLC-MS. The results suggested that BBR ameliorated the bile acid imbalance induced by DSS in the liver and gut. Furthermore, BBR treatment repaired gut barrier damage. The above results revealed that BBR alleviated DSS-induced UC in mice by restoring the disturbed gut microbiota, elevating unconjugated and secondary bile acids in the gastrointestinal tract, and activating the FXR and TGR5 signal pathway. This study provides novel insights into the mechanism of BBR in treating UC. [Display omitted] •Berberine suppressed colonic inflammation and increased gut barrier integrity.•Berberine reversed the imbalance of gut microbiota and bacterial metabolites.•Berberine regulated bile acid levels by increasing Lactobacillus and Roseburia.•Berberine modulated bile acid metabolism through activating FXR-TGR5 signaling.
doi_str_mv 10.1016/j.biopha.2023.115430
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2863305480</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0753332223012283</els_id><sourcerecordid>2863305480</sourcerecordid><originalsourceid>FETCH-LOGICAL-c385t-198e623ecccc30234ca55959c15a59d609c7d9bc8a3af6180827e0e3ed4d9f703</originalsourceid><addsrcrecordid>eNp9kLtOAzEQRS0EEiHwBxQuaTaM1-t9NEgQnlIkikBtee1ZMtE-gr1Byt_jaKmZZoqZe6R7GLsWsBAg8tvtoqZhtzGLFFK5EEJlEk7YTFQKkhygOGUzKJRMpEzTc3YRwhYAVC7LGWsf0NfoqUdO3c4PPxj443qdUO_2Fh23Q0sjBU4978girw-8G9y-NSP1X3zcIG_QmjapjR0jxiQe4y0Ga2qRG0uOdziaOmJCd8nOGtMGvPrbc_b5_PSxfE1W7y9vy_tVYmWpxkRUJeapRBtHxkaZNUpVqrJCGVW5HCpbuKq2pZGmyUUJZVogoESXuaopQM7ZzcSNhb73GEbdUbDYtqbHYR90WuZSgsrK42s2vVo_hOCx0TtPnfEHLUAf5eqtnuTqo1w9yY2xuymGscYPodfBEvbRGHm0o3YD_Q_4BXQ-hVg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2863305480</pqid></control><display><type>article</type><title>Berberine improves DSS-induced colitis in mice by modulating the fecal-bacteria-related bile acid metabolism</title><source>ScienceDirect Journals</source><creator>Sun, Xiongjie ; Zhang, Yu ; Cheng, Gang ; Zhu, Tianxiang ; Zhang, Zhigang ; Xiong, Lei ; Hu, Haiming ; Liu, Hongtao</creator><creatorcontrib>Sun, Xiongjie ; Zhang, Yu ; Cheng, Gang ; Zhu, Tianxiang ; Zhang, Zhigang ; Xiong, Lei ; Hu, Haiming ; Liu, Hongtao</creatorcontrib><description>Ulcerative colitis (UC) has been confirmed as a disease with a high incidence and low cure rate worldwide. In severe cases, UC can develop into colon cancer. Modern research has confirmed that berberine (BBR) can treat UC by inhibiting the expressions of inflammatory factors. However, the contribution of gut microbiota and flora metabolites in treating UC with BBR remains unclear. In this study, the ameliorative effects of BBR on gut microbiota dysbiosis and flora metabolites were investigated in a dextran sodium sulfate (DSS)-induced UC rodent model. We found that BBR significantly improved the pathological phenotype, attenuated intestinal barrier disruption, and mitigated colonic inflammation in DSS mice. By 16 S rDNA sequencing, BBR alleviated gut microbiota dysbiosis in UC mice. Moreover, the gut microbiota depletion experiment confirmed that the therapeutic effect of BBR was inextricably correlated with the gut microbiota. Besides, the flora metabolites (e.g., short-chain fatty acids, bile acids, and 5-hydroxytryptamine) were studied using HPLC-MS. The results suggested that BBR ameliorated the bile acid imbalance induced by DSS in the liver and gut. Furthermore, BBR treatment repaired gut barrier damage. The above results revealed that BBR alleviated DSS-induced UC in mice by restoring the disturbed gut microbiota, elevating unconjugated and secondary bile acids in the gastrointestinal tract, and activating the FXR and TGR5 signal pathway. This study provides novel insights into the mechanism of BBR in treating UC. [Display omitted] •Berberine suppressed colonic inflammation and increased gut barrier integrity.•Berberine reversed the imbalance of gut microbiota and bacterial metabolites.•Berberine regulated bile acid levels by increasing Lactobacillus and Roseburia.•Berberine modulated bile acid metabolism through activating FXR-TGR5 signaling.</description><identifier>ISSN: 0753-3322</identifier><identifier>EISSN: 1950-6007</identifier><identifier>DOI: 10.1016/j.biopha.2023.115430</identifier><language>eng</language><publisher>Elsevier Masson SAS</publisher><subject>Berberine ; Gut microbiota ; Intestinal metabolites, Bile acids ; Ulcerative colitis</subject><ispartof>Biomedicine &amp; pharmacotherapy, 2023-11, Vol.167, p.115430-115430, Article 115430</ispartof><rights>2023 The Authors</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c385t-198e623ecccc30234ca55959c15a59d609c7d9bc8a3af6180827e0e3ed4d9f703</citedby><cites>FETCH-LOGICAL-c385t-198e623ecccc30234ca55959c15a59d609c7d9bc8a3af6180827e0e3ed4d9f703</cites><orcidid>0000-0003-0149-6389</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Sun, Xiongjie</creatorcontrib><creatorcontrib>Zhang, Yu</creatorcontrib><creatorcontrib>Cheng, Gang</creatorcontrib><creatorcontrib>Zhu, Tianxiang</creatorcontrib><creatorcontrib>Zhang, Zhigang</creatorcontrib><creatorcontrib>Xiong, Lei</creatorcontrib><creatorcontrib>Hu, Haiming</creatorcontrib><creatorcontrib>Liu, Hongtao</creatorcontrib><title>Berberine improves DSS-induced colitis in mice by modulating the fecal-bacteria-related bile acid metabolism</title><title>Biomedicine &amp; pharmacotherapy</title><description>Ulcerative colitis (UC) has been confirmed as a disease with a high incidence and low cure rate worldwide. In severe cases, UC can develop into colon cancer. Modern research has confirmed that berberine (BBR) can treat UC by inhibiting the expressions of inflammatory factors. However, the contribution of gut microbiota and flora metabolites in treating UC with BBR remains unclear. In this study, the ameliorative effects of BBR on gut microbiota dysbiosis and flora metabolites were investigated in a dextran sodium sulfate (DSS)-induced UC rodent model. We found that BBR significantly improved the pathological phenotype, attenuated intestinal barrier disruption, and mitigated colonic inflammation in DSS mice. By 16 S rDNA sequencing, BBR alleviated gut microbiota dysbiosis in UC mice. Moreover, the gut microbiota depletion experiment confirmed that the therapeutic effect of BBR was inextricably correlated with the gut microbiota. Besides, the flora metabolites (e.g., short-chain fatty acids, bile acids, and 5-hydroxytryptamine) were studied using HPLC-MS. The results suggested that BBR ameliorated the bile acid imbalance induced by DSS in the liver and gut. Furthermore, BBR treatment repaired gut barrier damage. The above results revealed that BBR alleviated DSS-induced UC in mice by restoring the disturbed gut microbiota, elevating unconjugated and secondary bile acids in the gastrointestinal tract, and activating the FXR and TGR5 signal pathway. This study provides novel insights into the mechanism of BBR in treating UC. [Display omitted] •Berberine suppressed colonic inflammation and increased gut barrier integrity.•Berberine reversed the imbalance of gut microbiota and bacterial metabolites.•Berberine regulated bile acid levels by increasing Lactobacillus and Roseburia.•Berberine modulated bile acid metabolism through activating FXR-TGR5 signaling.</description><subject>Berberine</subject><subject>Gut microbiota</subject><subject>Intestinal metabolites, Bile acids</subject><subject>Ulcerative colitis</subject><issn>0753-3322</issn><issn>1950-6007</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kLtOAzEQRS0EEiHwBxQuaTaM1-t9NEgQnlIkikBtee1ZMtE-gr1Byt_jaKmZZoqZe6R7GLsWsBAg8tvtoqZhtzGLFFK5EEJlEk7YTFQKkhygOGUzKJRMpEzTc3YRwhYAVC7LGWsf0NfoqUdO3c4PPxj443qdUO_2Fh23Q0sjBU4978girw-8G9y-NSP1X3zcIG_QmjapjR0jxiQe4y0Ga2qRG0uOdziaOmJCd8nOGtMGvPrbc_b5_PSxfE1W7y9vy_tVYmWpxkRUJeapRBtHxkaZNUpVqrJCGVW5HCpbuKq2pZGmyUUJZVogoESXuaopQM7ZzcSNhb73GEbdUbDYtqbHYR90WuZSgsrK42s2vVo_hOCx0TtPnfEHLUAf5eqtnuTqo1w9yY2xuymGscYPodfBEvbRGHm0o3YD_Q_4BXQ-hVg</recordid><startdate>202311</startdate><enddate>202311</enddate><creator>Sun, Xiongjie</creator><creator>Zhang, Yu</creator><creator>Cheng, Gang</creator><creator>Zhu, Tianxiang</creator><creator>Zhang, Zhigang</creator><creator>Xiong, Lei</creator><creator>Hu, Haiming</creator><creator>Liu, Hongtao</creator><general>Elsevier Masson SAS</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0149-6389</orcidid></search><sort><creationdate>202311</creationdate><title>Berberine improves DSS-induced colitis in mice by modulating the fecal-bacteria-related bile acid metabolism</title><author>Sun, Xiongjie ; Zhang, Yu ; Cheng, Gang ; Zhu, Tianxiang ; Zhang, Zhigang ; Xiong, Lei ; Hu, Haiming ; Liu, Hongtao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c385t-198e623ecccc30234ca55959c15a59d609c7d9bc8a3af6180827e0e3ed4d9f703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Berberine</topic><topic>Gut microbiota</topic><topic>Intestinal metabolites, Bile acids</topic><topic>Ulcerative colitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sun, Xiongjie</creatorcontrib><creatorcontrib>Zhang, Yu</creatorcontrib><creatorcontrib>Cheng, Gang</creatorcontrib><creatorcontrib>Zhu, Tianxiang</creatorcontrib><creatorcontrib>Zhang, Zhigang</creatorcontrib><creatorcontrib>Xiong, Lei</creatorcontrib><creatorcontrib>Hu, Haiming</creatorcontrib><creatorcontrib>Liu, Hongtao</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biomedicine &amp; pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sun, Xiongjie</au><au>Zhang, Yu</au><au>Cheng, Gang</au><au>Zhu, Tianxiang</au><au>Zhang, Zhigang</au><au>Xiong, Lei</au><au>Hu, Haiming</au><au>Liu, Hongtao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Berberine improves DSS-induced colitis in mice by modulating the fecal-bacteria-related bile acid metabolism</atitle><jtitle>Biomedicine &amp; pharmacotherapy</jtitle><date>2023-11</date><risdate>2023</risdate><volume>167</volume><spage>115430</spage><epage>115430</epage><pages>115430-115430</pages><artnum>115430</artnum><issn>0753-3322</issn><eissn>1950-6007</eissn><abstract>Ulcerative colitis (UC) has been confirmed as a disease with a high incidence and low cure rate worldwide. In severe cases, UC can develop into colon cancer. Modern research has confirmed that berberine (BBR) can treat UC by inhibiting the expressions of inflammatory factors. However, the contribution of gut microbiota and flora metabolites in treating UC with BBR remains unclear. In this study, the ameliorative effects of BBR on gut microbiota dysbiosis and flora metabolites were investigated in a dextran sodium sulfate (DSS)-induced UC rodent model. We found that BBR significantly improved the pathological phenotype, attenuated intestinal barrier disruption, and mitigated colonic inflammation in DSS mice. By 16 S rDNA sequencing, BBR alleviated gut microbiota dysbiosis in UC mice. Moreover, the gut microbiota depletion experiment confirmed that the therapeutic effect of BBR was inextricably correlated with the gut microbiota. Besides, the flora metabolites (e.g., short-chain fatty acids, bile acids, and 5-hydroxytryptamine) were studied using HPLC-MS. The results suggested that BBR ameliorated the bile acid imbalance induced by DSS in the liver and gut. Furthermore, BBR treatment repaired gut barrier damage. The above results revealed that BBR alleviated DSS-induced UC in mice by restoring the disturbed gut microbiota, elevating unconjugated and secondary bile acids in the gastrointestinal tract, and activating the FXR and TGR5 signal pathway. This study provides novel insights into the mechanism of BBR in treating UC. [Display omitted] •Berberine suppressed colonic inflammation and increased gut barrier integrity.•Berberine reversed the imbalance of gut microbiota and bacterial metabolites.•Berberine regulated bile acid levels by increasing Lactobacillus and Roseburia.•Berberine modulated bile acid metabolism through activating FXR-TGR5 signaling.</abstract><pub>Elsevier Masson SAS</pub><doi>10.1016/j.biopha.2023.115430</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-0149-6389</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0753-3322
ispartof Biomedicine & pharmacotherapy, 2023-11, Vol.167, p.115430-115430, Article 115430
issn 0753-3322
1950-6007
language eng
recordid cdi_proquest_miscellaneous_2863305480
source ScienceDirect Journals
subjects Berberine
Gut microbiota
Intestinal metabolites, Bile acids
Ulcerative colitis
title Berberine improves DSS-induced colitis in mice by modulating the fecal-bacteria-related bile acid metabolism
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T07%3A26%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Berberine%20improves%20DSS-induced%20colitis%20in%20mice%20by%20modulating%20the%20fecal-bacteria-related%20bile%20acid%20metabolism&rft.jtitle=Biomedicine%20&%20pharmacotherapy&rft.au=Sun,%20Xiongjie&rft.date=2023-11&rft.volume=167&rft.spage=115430&rft.epage=115430&rft.pages=115430-115430&rft.artnum=115430&rft.issn=0753-3322&rft.eissn=1950-6007&rft_id=info:doi/10.1016/j.biopha.2023.115430&rft_dat=%3Cproquest_cross%3E2863305480%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c385t-198e623ecccc30234ca55959c15a59d609c7d9bc8a3af6180827e0e3ed4d9f703%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2863305480&rft_id=info:pmid/&rfr_iscdi=true